Table 1.
Baseline disease and immunotherapy characteristics.
| Variable | Patients (N = 522) |
|---|---|
| Age (in years) | |
| Median (range) | 63 (19–90) |
| Sex, n (%) | 360 (69) |
| Male | 162 (31) |
| Female | |
| Race, n (%) | 496 (95) |
| White | 16 (3) |
| Black | 10 (2) |
| Other | |
| ECOG performance status at diagnosis, n (%) | |
| 0 | 99 (19) |
| 1 | 84 (16) |
| 2 | 10 (2) |
| Unknown | 329 (63) |
| Cancer type, n (%) | |
| Renal cell carcinoma | 149 (28.5%) |
| Non-small cell lung cancer | 128 (24.5%) |
| Melanoma | 125 (23.9%) |
| Head and neck cancer | 120 (23.0%) |
| Prior systemic therapy, n (%) | |
| 1 Prior line | 198 (38) |
| 2+ Prior line | 324 (62) |
| First Immune checkpoint inhibitors, n (%) | |
| Nivolumab | 219 (42.0%) |
| Pembrolizumab | 202 (38.7%) |
| Ipilimumab + nivolumab | 69 (13.2%) |
| Ipilimumab | 30 (5.6%) |
| Avelumab | 1 (0.2%) |
| Cemiplimab | 1 (0.2%) |
ECOG: Eastern Cooperative Oncology Group. 0: Fully active; no performance restrictions; 1: strenuous physical activity restricted; fully ambulatory and able to carry out light work; 2: capable of all self-care but unable to carry out any work activities, and up and about for >50% of waking hours; 3: capable of only limited self-care, and confined to bed or chair for >50% of waking hours; 4: completely disabled, cannot carry out any self-care, and totally confined to bed or chair.